Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck

Annals of Oncology

Volumn 21, Issue 2, 2010, Pages 342-347

  Wirth, L J ^a   Allen, A M ^b   Posner, M R ^b   Haddad, R I ^b   Li, Y ^b   Clark, J R ^a   Busse, P M ^a   Chan, A W ^a   Goguen, L A ^c   Norris, C M ^c   Annino, D J ^c   Tishler, R B ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Chemoradiotherapy; Locoregionally advanced head and neck cancer; Panitumumab

Indexed keywords

CARBOPLATIN; PACLITAXEL; PANITUMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACNE; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; FATIGUE; FEMALE; FEVER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPERGLYCEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; INTENSITY MODULATED RADIATION THERAPY; MALE; MAXIMUM TOLERATED DOSE; MOUTH PAIN; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DERMATITIS; SIDE EFFECT; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION; XEROSTOMIA; CLINICAL TRIAL; DISEASE COURSE; HEAD AND NECK TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PATIENT COMPLIANCE; SQUAMOUS CELL CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS, SQUAMOUS CELL; PACLITAXEL; PATIENT COMPLIANCE; RADIOTHERAPY, INTENSITY-MODULATED; TREATMENT OUTCOME;

EID: 77949446869     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp477     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71-96.
2. Argiris A, Karamouzis MV, Raben D, Ferris RL. Head and neck cancer. Lancet 2008; 371(9625): 1695-1709.
3. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three metaanalyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355(9208): 949-955.
4. Brizel DM, Albers ME, Fisher SR et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998; 338(25): 1798-1804.
5. Adelstein DJ, Li Y, Adams GL et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003; 21(1): 92-98.
6. Staar S, Rudat V, Stuetzer H et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy-results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001; 50(5): 1161-1171.
7. Arico S, Pattingre S, Bauvy C et al. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer cell line HT-29. J Biol Chem 2002; 277(31): 27613-27621.
8. Brizel DM, Esclamado R. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol 2006; 24(17): 2612-2617.
9. Mendenhall WM, Amdur RJ, Palta JR. Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 2006; 24(17): 2618-2623.
10. van Zandwijk N, Dalesio O, Pastorino U et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000; 92(12): 977-986.
11. Nguyen NP, Frank C, Moltz CC et al. Aspiration rate following chemoradiation for head and neck cancer: an underreported occurrence. Radiother Oncol 2006; 80(3): 302-306.
12. Murphy BA, Gilbert J, Cmelak A, Ridner SH. Symptom control issues and supportive care of patients with head and neck cancers. Clin Adv Hematol Oncol 2007; 5(10): 807-822.
13. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993; 53(15): 3579-3584.
14. Grandis JR, Melhem MF, Gooding WE et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90(11): 824-832.
15. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002; 62(24): 7350-7356.
16. Cohen EE. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24(17): 2659-2665.
17. Milas L, Mason KA, Ang KK. Epidermal growth factor receptor and its inhibition in radiotherapy: in vivo findings. Int J Radiat Biol 2003; 79(7): 539-545.
18. Robert F, Ezekiel MP, Spencer SA et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001; 19(13): 3234-3243.
19. Trigo J, Hitt R, Koralewski P et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a phase II study. Proc Am Soc Clin Oncol 2004; 22(14S): 488s (Abstr 5502).
20. Yang XD, Jia XC, Corvalan JR et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38(1): 17-23.
21. Foon KA, Yang XD, Weiner LM et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58(3): 984-990.
22. Rowinsky EK, Schwartz GH, Gollob JA et al. Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. J Clin Oncol 2004; 22(15): 3003-3015.
23. Van Cutsem E, Peeters M, Siena S et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25(13): 1658-1664.
24. Kruser TJ, Armstrong E, Huang S et al. Panitumumab, a fully human anti-EGFR monoclonal antibody, augments radiation response in xenograft models of upper aerodigestive tract cancers. Int J Radiat Oncol Biol Phys 2007; 69(3): S615-S616.
25. Medeiros F, Yuan L, Breslin G et al. Type-specific HPV testing as a predictor of high-grade squamous intraepithelial lesion outcome after cytologic abnormalities. J Low Genit Tract Dis 2005; 9(3): 154-159.
26. Bentzen SM, Trotti A. Evaluation of early and late toxicities in chemoradiation trials. J Clin Oncol 2007; 25(26): 4096-4103.
27. Budach W, Bolke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 2007; 357(5): 514-515.
28. Berger B, Belka C. Severe skin reaction secondary to concomitant radiotherapy plus cetuximab. Radiat Oncol 2008; 3: 5.
29. Giro C, Berger B, Bolke E et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 2009; 90(2): 166-71.
30. Pryor DI, Porceddu SV, Burmeister BH et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol 2009; 90(2): 172-176.
31. Ang K, Pajak T, Rosenthal DI et al. A phase III trial to compare standard versus accelerated fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG 0129): report of compliance and toxicity. Int J Radiat Oncol Biol Phys 2007; 69(3): S12-S13.
32. Ringstrom E, Peters E, Hasegawa M et al. Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 2002; 8(10): 3187-3192.
33. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100(4): 261-269.